#1 Clinical Trials Search in Europe

Apomorphine Hydrochloride Hemihydrate

Apomorphine Hydrochloride Hemihydrate is a drug currently being studied in clinical trials for its potential to improve consciousness in patients with severe brain injuries and disorders of consciousness. These trials aim to investigate the drug’s ability to boost recovery, enhance arousal, and increase awareness in comatose patients. The studies focus on patients with acute traumatic and non-traumatic brain injuries, exploring the drug’s effects on clinical consciousness levels and various biomarkers.

Table of Contents

What is Apomorphine Hydrochloride Hemihydrate?

Apomorphine Hydrochloride Hemihydrate is a medication that belongs to a class of drugs called dopamine agonists. It is primarily known for its use in treating Parkinson’s disease, but recent research is exploring its potential in treating disorders of consciousness[1]. Apomorphine is available as a solution for infusion, which means it can be administered directly into the bloodstream through a small needle under the skin (subcutaneous injection)[2].

Medical Conditions Treated

Current research is investigating the use of Apomorphine Hydrochloride Hemihydrate for treating:

  • Coma and other disorders of consciousness due to acute traumatic and non-traumatic brain injury[1]
  • Unresponsive wakefulness syndrome (formerly known as vegetative state)
  • Minimally conscious state[3]
These conditions are serious states where a person’s consciousness is severely impaired, often due to severe brain injury.

How It Works

Apomorphine is thought to work by stimulating dopamine receptors in the brain. Dopamine is a neurotransmitter (a chemical messenger) that plays a crucial role in various brain functions, including arousal and awareness. By mimicking the action of dopamine, Apomorphine may help to “boost” or stimulate brain activity in patients with impaired consciousness[1][3].

Ongoing Research

Several clinical trials are currently underway to investigate the effectiveness of Apomorphine in treating disorders of consciousness:

  1. The BREA2KTHROUGH trial is studying whether Apomorphine, in combination with another substance called psilocybin, can improve levels of consciousness in comatose patients[1].
  2. The BREA2KTHROUGH DOSEFINDER study is a dose-finding study to establish the safety of using Apomorphine and psilocybin in unresponsive ICU patients with acute brain injury[2].
  3. Another study is investigating the efficacy of Apomorphine subcutaneous infusions for treating patients with disorders of consciousness, aiming to identify biomarkers that correlate with responsiveness to the therapy[3].
These studies are still in progress, and their results will help determine the effectiveness and safety of Apomorphine for these conditions.

Administration and Dosage

Apomorphine is typically administered as a subcutaneous injection, which means it’s injected just under the skin. The exact dosage can vary depending on the specific study and patient condition. For example:

  • In one study, the maximum daily dose is set at 14.4 ml of a 5 mg/ml solution[3].
  • Another study is testing different doses (1mg, 10mg, and 25mg) to determine the most effective and safe dose[2].
It’s important to note that these dosages are part of clinical trials and may not reflect the final recommended dosage if the drug is approved for this use.

Potential Benefits

The potential benefits being investigated in these studies include:

  • Improved levels of consciousness[1]
  • Faster awakening from coma[2]
  • Better clinical outcomes and quality of life[3]
  • Improved brain activity as measured by various neuroimaging techniques[3]
However, it’s crucial to remember that these potential benefits are still being studied and have not yet been conclusively proven.

Possible Side Effects and Precautions

As with any medication, Apomorphine may cause side effects. Some potential risks being monitored in these studies include:

  • Cardiovascular effects, particularly changes in heart rhythm[3]
  • Neuropsychiatric effects[3]
  • Other serious adverse events or reactions[1][2][3]
The studies are carefully monitoring patients for these and other potential side effects to ensure patient safety.

Patient Eligibility

The ongoing studies have specific criteria for patient eligibility. Generally, patients who might be considered for these trials include:

  • Adults (typically 18-70 years old) with disorders of consciousness due to brain injury[3]
  • Patients whose condition is expected to last for 3 or more days[1][2]
  • Patients who are not under continuous pharmacological sedation[1][2]
However, there are also several exclusion criteria, such as certain medical conditions or use of specific medications. The decision to participate in such a trial should always be made in consultation with healthcare professionals and with informed consent from the patient’s legal representative.

Aspect Details
Drug Name Apomorphine Hydrochloride Hemihydrate
Target Conditions Coma and disorders of consciousness due to acute traumatic and non-traumatic brain injury
Trial Phases Phase 1 (dose-finding) and Phase 2b
Administration Method Subcutaneous injection or infusion
Primary Objectives Improve clinical levels of consciousness, establish safety, identify responders
Key Outcome Measures CRS-R scores, EEG patterns, PET signals, MRI functional connectivity, GOS-E scores
Inclusion Criteria Clinically unresponsive ICU patients with expected unconsciousness ≥3 days
Exclusion Criteria Continuous pharmacological sedation, expected survival <7 days, lack of consent

FAQ

  • What is Apomorphine Hydrochloride Hemihydrate used for in these clinical trials? In these clinical trials, Apomorphine Hydrochloride Hemihydrate is being studied for its potential to improve consciousness in patients with severe brain injuries and disorders of consciousness, including coma patients. The drug is being investigated for its ability to enhance arousal and awareness in these patients.
  • Who are the target patients for these clinical trials? The target patients are clinically unresponsive individuals admitted to the ICU with either traumatic or non-traumatic brain injuries, or those with systemic medical or surgical conditions causing non-medically induced coma. The trials focus on patients whose unconsciousness is expected to last for 3 days or more.
  • How is the drug administered in these trials? Apomorphine Hydrochloride Hemihydrate is administered through subcutaneous injection or infusion. The exact dosage and administration method may vary between trials, with some studies exploring different doses to establish safety and efficacy.
  • What are the main objectives of these clinical trials? The main objectives of these trials include investigating if Apomorphine can improve clinical levels of consciousness, studying its effects on proxy biomarkers of consciousness, establishing its safety in unresponsive ICU patients, and identifying potential responders to the treatment.
  • What are some of the outcome measures used in these trials? The trials use various outcome measures, including changes in consciousness levels measured by scales like the Coma Recovery Scale-Revised (CRS-R), changes in EEG patterns, PET signal changes, MRI functional connectivity, and improvements in clinical outcomes such as the Glasgow Outcome Scale-Extended (GOS-E).

Ongoing Clinical Trials on Apomorphine Hydrochloride Hemihydrate

  • Study of apomorphine and rifaximin for Parkinson’s disease patients with reduced levodopa effectiveness

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Apomorphine Hydrochloride and Sodium Chloride for Patients with Severe Brain Injury and Disorders of Consciousness

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Spain

  • Study on Apomorphine and Psilocybin for Recovery in Coma Patients with Acute Brain Injury

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Psilocybin and Apomorphine for Improving Consciousness in Patients with Coma and Brain Injury

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Apomorphine Hydrochloride Hemihydrate: A medication being studied for its potential to improve consciousness in patients with severe brain injuries. It is typically used to treat Parkinson's disease but is being explored for new applications in these trials.
  • Coma: A state of deep unconsciousness where a person cannot be awakened and does not respond to stimuli.
  • Disorders of Consciousness: A range of conditions affecting a person's level of awareness, including coma, vegetative state, and minimally conscious state.
  • ICU: Intensive Care Unit, a special department in hospitals that provides intensive care medicine to critically ill patients.
  • CRS-R: Coma Recovery Scale-Revised, a standardized assessment tool used to measure consciousness levels in patients with severe brain injuries.
  • EEG: Electroencephalogram, a test that records electrical activity in the brain.
  • PET: Positron Emission Tomography, an imaging test that uses a radioactive tracer to evaluate organ and tissue functions.
  • MRI: Magnetic Resonance Imaging, a medical imaging technique that uses strong magnetic fields and radio waves to produce detailed images of the body.
  • GOS-E: Glasgow Outcome Scale-Extended, a scale used to assess functional outcome in patients after brain injury.
  • Subcutaneous: Beneath the skin. In these trials, it refers to the method of administering the drug by injection or infusion under the skin.

References

  1. http://clinicaltrials.eu/trial/study-on-psilocybin-and-apomorphine-for-improving-consciousness-in-patients-with-coma-and-brain-injury/
  2. http://clinicaltrials.eu/trial/study-on-apomorphine-and-psilocybin-for-recovery-in-coma-patients-with-acute-brain-injury/
  3. http://clinicaltrials.eu/trial/study-on-apomorphine-hydrochloride-and-sodium-chloride-for-patients-with-severe-brain-injury-and-disorders-of-consciousness/